Role of therapy or monitoring in preventing progression to gastric cancer

Journal of Clinical Gastroenterology

Volumn 36, Issue 5 SUPPL., 2003, Pages

  Zivny, Jaroslav ^a   Wang, Timothy C ^a   Yantiss, Rhonda ^a   Kim, Kyung H ^a   Houghton, JeanMarie ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Dysplasia; Gastric cancer; Helicobacter pylori; Surveillance

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CYCLOOXYGENASE 2; MOLYBDENUM; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOL; RIBOFLAVIN; SELENIUM; ZINC;

ANTIBIOTIC THERAPY; ATROPHY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DISEASE ASSOCIATION; EPITHELIUM DYSPLASIA; ERADICATION THERAPY; FOOD PRESERVATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HIGH SODIUM INTAKE; HUMAN; INTESTINE METAPLASIA; MONITORING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCREENING; STOMACH ACID SECRETION; STOMACH CANCER; STOMACH EPITHELIUM;

ADENOCARCINOMA; ANIMALS; DISEASE PROGRESSION; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; MONITORING, PHYSIOLOGIC; RISK FACTORS; STOMACH NEOPLASMS;

EID: 0037404398     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200305001-00009     Document Type: Conference Paper

References (92)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996;23:281-91.
3. Chan AO, Wong BC, Lam SK. Gastric cancer: Past, present and future. Can J Gastroenterol 2001;15:469-74.
4. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.
5. Lauwers GY, Shimizu M, Correa P, et al. Evaluation of gastric biopsies for neoplasia: Differences between Japanese and Western pathologists. Am J Surg Pathol 1999;23:511-8.
6. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
7. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
8. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ 1991;302:1302-5.
9. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
10. Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
11. Huang JQ, Sridhar S, Chen Y, et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
12. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999;13:851-6.
13. Ekstrom AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001;121:784-91.
14. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
15. Fox JG, Wishnok JS, Murphy JC, et al. MNNG-induced gastric carcinoma in ferrets infected with Helicobacter mustelae. Carcinogenesis 1993;14:1957-61.
16. Roth KA, Kapadia SB, Martin SM, et al. Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. J Immunol 1999;163:1490-7.
17. Eaton KA, Mefford M, Thevenot T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol 2001;166:7456-61.
18. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
19. Fox JG, Beck P, Dangler CA, et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat Med 2000;6:536-42.
20. Yamaoka Y, Kita M, Kodama T, et al. Expression of cytokine mRNA in gastric mucosa with Helicobacter pylori infection. Scand J Gastroenterol 1995;30:1153-9.
21. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000;118:36-47.
22. Farinati F, Cardin R, Degan P, et al. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut 1998;42:351-6.
23. Baik SC, Youn HS, Chung MH, et al. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Cancer Res 1996;56:1279-82.
24. Moss SF, Calam J, Agarwal B, et al. Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 1996;38:498-501.
25. Wagner S, Beil W, Westermann J, et al. Regulation of gastric epithelial cell growth by Helicobacter pylori: Offense for a major role of apoptosis. Gastroenterology 1997;113:1836-47.
26. Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999;116:1319-29.
27. Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157:729-35.
28. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-9.
29. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46:615-21.
30. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
31. Lehtola J. Family study of gastric carcinoma: With special reference to histologic types. Scand J Gastroenterol Suppl 1978;50:3-54.
32. El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000;118:22-30.
33. Enders KWN, Chan WY, Auyeung A, et al. Increased frequency of pre-malignant gastric lesions in first degree relatives of stomach cancer patients. Gastroenterology 2002;122(suppl 1):abstract 136.
34. Ebert MP, Malfertheiner P. Pathogenesis of sporadic and familial gastric cancer - implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002;16:1059-66.
35. Park WS, Oh RR, Park JY, et al. Somatic mutations of the trefoil factor family I gene in gastric cancer. Gastroenterology 2000;119:691-8.
36. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
37. Arista-Nasr J, Jimenez-Rosas F, Uribe-Uribe N, et al. Pathological disorders of the gastric mucosa surrounding carcinomas and primary lymphomas. Am J Gastroenterol 2001;96:1746-50.
38. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
39. Tahara E. Molecular biology of gastric cancer. World J Surg 1995;19:484-8; discussion 489-90.
40. Ming SC. Dysplasia of gastric epithelium. Front Gastrointest Res 1979;4:164-72.
41. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut 1999;45:784-90.
42. Oehlert W, Keller P, Henke M, et al. Gastric mucosal dysplasia: what is its clinical significance? Front Gastrointest Res 1979;4:173-82.
43. Schmidt PH, Lee JR, Joshi V, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 1999;79:639-46.
44. You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993;53:1317-21.
45. Morales TG, Sampliner RE, Camargo E, et al. Inability to noninvasively diagnose gastric intestinal metaplasia in Hispanics or reverse the lesion with Helicobacter pylori eradication. J Clin Gastroenterol 2001;32:400-4.
46. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32:1110-3.
47. Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002;50:378-81.
48. Faraji EI, Frank BB. Multifocal atrophic gastritis and gastric carcinoma. Gastroenterol Clin North Am 2002;31:499-516.
49. Farinati F, Rugge M, Di Mario F, et al. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D. - Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy 1993;25:261-4.
50. Bearzi I, Brancorsini D, Santinelli A, et al. Gastric dysplasia: A ten-year follow-up study. Pathol Res Pract 1994;190:61-8.
51. Saraga EP, Gardiol D, Costa J. Gastric dysplasia. A histologic follow-up study. Am J Surg Pathol 1987;11:788-96.
52. Fertitta AM, Comin U, Terruzzi V, et al. Clinical significance of gastric dysplasia: A multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group. Endoscopy 1993;25:265-8.
53. Rugge M, Farinati F, Baffa R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994;107:1288-96.
54. Lansdown M, Quirke P, Dixon MF, et al. High-grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut 1990;31:977-83.
55. Di Gregorio C, Morandi P, Fante R, et al. Gastric dysplasia. A follow-up study. Am J Gastroenterol 1993;88:1714-9.
56. Weinstein WM, Goldstein NS. Gastric dysplasia and its management. Gastroenterology 1994;107:1543-5.
57. Offerhaus GJ, Tersmette AC, Huibregtse K, et al. Mortality caused by stomach cancer after remote partial gastrectomy for benign conditions: 40 years of follow up of an Amsterdam cohort of 2633 postgastrectomy patients. Gut 1988;29:1588-90.
58. Greene FL. Neoplastic changes in the stomach after gastrectomy. Surg Gynecol Obstet 1990;171:477-80.
59. Tersmette AC, Giardiello FM, Tytgat GN, et al. Carcinogenesis after remote peptic ulcer surgery: The long-term prognosis of partial gastrectomy. Scand J Gastroenterol Suppl 1995;212:96-9.
60. Shimizu N, Ikehara Y, Inada K, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 2000;60:1512-4.
61. Nozaki K, Shimizu N, Tsukamoto T, et al. Reversibility of heterotopic proliferative glands in glandular stomach of Helicobacter pylori-infected Mongolian gerbils on eradication. Jpn J Cancer Res 2002;93:374-81.
62. Keto Y, Ebata M, Okabe S. Gastric mucosal changes induced by long term infection with Helicobacterpylori in Mongolian gerbils: Effects of bacteria eradication. J Physiol 2001;95:429-36.
63. Zavros Y, Rieder G, Ferguson A, et al. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology 2002;122:119-33.
64. Zavros Y, Rieder G, Ferguson A, et al. Hypergastrinemia in response to gastric inflammation suppresses somatostatin. Am J Physiol Gastrointest Liver Physiol 2002;282:G175-83.
65. Correa P, Malcom G, Schmidt B, et al. Review article: Antioxidant micronutrients and gastric cancer. Aliment Pharmacol Ther 1998;12(suppl 1):73-82.
66. Hwang H, Dwyer J, Russell RM. Diet, Helicobacter pylori infection, food preservation and gastric cancer risk: Are there new roles for preventative factors? Nutr Rev 1994;52:75-83.
67. You WC, Zhang L, Gail MH, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000;92:1607-12.
68. Stahelin HB, Gey KF, Eichholzer M, et al. Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year follow-up of the prospective Basel Study. Am J Epidemiol 1991;133:766-75.
69. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
70. Blot WJ. Preventing cancer by disrupting progression of precancerous lesions. J Natl Cancer Inst 2000;92:1868-9.
71. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92.
72. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1055-62.
73. Anonymous. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
74. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
75. van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002:196:171-9.
76. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study. Gastroenterology 2000;119:7-14.
77. Wong BCY, Lam SK, Wong WM, et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high-risk population: A 5-year prospective randomized study. Gastroenterology 2002;122:abstract 106581.
78. Sung JJY LS, Leung WK, Enders KWN, et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. Gastroenterology 2002;122(suppl 1):abstract S1142.
79. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6.
80. Wong BCY, Lam SK, Wong WM, et al. Eradicating Helicobacter pylori infection in general population prevents gastric cancer: 7-year prospective randomized placebo-controlled study. Gastroenterology 2002;122:abstract 106557.
81. van der Hulst RW, van der Ende A, Dekker FW, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: A prospective 1-year follow-up study. Gastroenterology 1997;113:25-30.
82. Tucci A, Poli L, Tosetti C, et al. Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol 1998;93:1425-31.
83. Genta RM, Lew GM, Graham DY. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993;6:281-9.
84. Haruma K, Mihara M, Kamada T, et al. Eradication of Helicobacter pylori reverses intestinal metaplasia in patients with severe atrophic gastritis. Gastroenterology 1997;112:A142.
85. Griffiths AE, Thursz MR, Walker MM. Do intestinal metaplasia and glandular atrophy reverse after H. pylori eradication? Gut 1997;41:A48.
86. Ierardi E, Balzano I, Traversa A, et al. Lack of reversibility of epithelial proliferative changes after Helicobacter pylori eradication in areas of intestinal metaplasia. Gut 1996;39(suppl 2):A18.
87. Forbes GM, Warren JR, Glaser ME, et al. Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol 1996:11: 670-3.
88. Tepes B, Kavcic B, Zaletel LK, et al. Two- to four-year histologic follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999;188:24-9.
89. Zerbib F, Lenk C, Sawan B, et al. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients. Eur J Gastroenterol Hepatol 2000;12:719-25.
90. Dixon MF. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut 2001;49:2-4.
91. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
92. Parsonnet J, Harris RA, Hack HM, et al. Modeling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996;348:150-4.